# M2: å¾ªè­‰é†«å­¸ç­‰ç´šæ•æ„Ÿæ€§
# EBM Hierarchy Sensitivity: Do LLMs Respect the Evidence Pyramid?

> **å±¤ç´š**ï¼šLayer 1 â€” è¡¨é¢æ€§èƒ½è©•ä¼°
> **è²¡ç¶“å°æ‡‰**ï¼šI2 (Behavioral Biases in LLMs)
> **ç‹€æ…‹**ï¼šğŸŸ¡ Partially Ready â€” éœ€å»ºæ§‹ 180 å€‹è‡¨åºŠæƒ…å¢ƒ
> **Phase**ï¼šPhase 3ï¼ˆå—ç›Šæ–¼ M7 æ–¹æ³•è«–ï¼‰

---

## ç ”ç©¶å•é¡Œ (Research Problem)

å¾ªè­‰é†«å­¸ï¼ˆEvidence-Based Medicine, EBMï¼‰çš„æ ¸å¿ƒåŸå‰‡æ˜¯è­‰æ“šæœ‰ç­‰ç´šä¹‹åˆ†ï¼šç³»çµ±æ€§å›é¡§èˆ‡ RCT å„ªæ–¼è§€å¯Ÿæ€§ç ”ç©¶ï¼Œè§€å¯Ÿæ€§ç ”ç©¶å„ªæ–¼ç—…ä¾‹å ±å‘Šï¼Œç—…ä¾‹å ±å‘Šå„ªæ–¼å°ˆå®¶æ„è¦‹ã€‚é€™å€‹è­‰æ“šé‡‘å­—å¡”æ˜¯ç¾ä»£è‡¨åºŠæ±ºç­–çš„åŸºçŸ³ã€‚

**ä½† LLM æ˜¯å¦å…§åŒ–äº†é€™å€‹ç­‰ç´šï¼Ÿ** ç•¶æ¨¡å‹åŒæ™‚æ¥æ”¶åˆ°é«˜å“è³ªï¼ˆRCTï¼‰èˆ‡ä½å“è³ªï¼ˆanecdotalï¼‰è­‰æ“šæ™‚ï¼Œæ˜¯å¦æœƒæ­£ç¢ºåœ°å°é«˜å“è³ªè­‰æ“šçµ¦äºˆæ›´å¤§æ¬Šé‡ï¼Ÿæˆ–è€…ï¼Œæ¨¡å‹æœƒè¢«ä»¥ä¸‹å› ç´ èª¤å°ï¼š
- ç”Ÿå‹•çš„å€‹æ¡ˆæè¿°ï¼ˆnarrative persuasionï¼‰
- æ¬Šå¨äººç‰©çš„æ„è¦‹ï¼ˆauthority biasï¼‰
- æœ€è¿‘ç™¼è¡¨çš„ç ”ç©¶ï¼ˆrecency biasï¼‰
- å¤§æ•¸å­—çš„èª˜å°ï¼ˆsample size neglect çš„åé¢ï¼‰

**é€™å€‹å•é¡Œçš„è‡¨åºŠé‡è¦æ€§ä¸è¨€è€Œå–»ï¼š** å¦‚æœ LLM åœ¨è‡¨åºŠå»ºè­°ä¸­ä¸æ°ç•¶åœ°å¼•ç”¨ä½å“è³ªè­‰æ“šï¼Œæˆ–è¢«æ•˜è¿°æ€§æ¡ˆä¾‹èªªæœè€Œå¿½ç•¥ RCT çµè«–ï¼Œå¯èƒ½å°è‡´éæœ€ä½³æ²»ç™‚æ±ºç­–ã€‚

**å…·é«”æœªçŸ¥ï¼š**
1. LLM åœ¨é¢å°ç›¸äº’çŸ›ç›¾çš„ä¸åŒç­‰ç´šè­‰æ“šæ™‚ï¼Œæ˜¯å¦ç³»çµ±æ€§åœ°åå¥½é«˜å“è³ªè­‰æ“šï¼Ÿ
2. å“ªç¨®åèª¤æ“æ§æœ€èƒ½å‹•æ– LLM çš„è­‰æ“šç­‰ç´šåˆ¤æ–·ï¼Ÿ
3. çµæ§‹åŒ–çš„ EBM prompt engineering èƒ½å¦æœ‰æ•ˆ debiasï¼Ÿ
4. ä¸åŒæ¨¡å‹åœ¨è­‰æ“šç­‰ç´šæ•æ„Ÿæ€§ä¸Šæ˜¯å¦æœ‰ç³»çµ±æ€§å·®ç•°ï¼Ÿ

---

## æ ¸å¿ƒæ–¹æ³• (Core Approach)

### 1. EBM è­‰æ“šç­‰ç´šå®šç¾©

æ¡ç”¨ Sackett (1996) + GRADE (2004) èåˆæ¡†æ¶ï¼š

| ç­‰ç´š | è­‰æ“šé¡å‹ | GRADE ç­‰ç´š | ç¯„ä¾‹ |
|------|---------|-----------|------|
| Level I | ç³»çµ±æ€§å›é¡§ / Meta-analysis | High âŠ•âŠ•âŠ•âŠ• | Cochrane Review of antihypertensive RCTs |
| Level II | å–®ä¸€ RCTï¼ˆå¤§æ¨£æœ¬ã€å¤šä¸­å¿ƒï¼‰ | High âŠ•âŠ•âŠ•âŠ• | N=5000 double-blind RCT |
| Level III | è§€å¯Ÿæ€§ç ”ç©¶ï¼ˆcohort / case-controlï¼‰ | Moderate âŠ•âŠ•âŠ•â—‹ | Retrospective cohort, N=800 |
| Level IV | ç—…ä¾‹ç³»åˆ— / ç—…ä¾‹å ±å‘Š | Low âŠ•âŠ•â—‹â—‹ | Case report of 3 patients |
| Level V | å°ˆå®¶æ„è¦‹ / æ©Ÿåˆ¶æ¨ç† | Very Low âŠ•â—‹â—‹â—‹ | Expert commentary, pathophysiological argument |

### 2. å…­ç¨®è­‰æ“šåèª¤æ¸¬è©¦ (Six Evidence Bias Tests)

æ¯ç¨®åèª¤è¨­è¨ˆç‚ºä¸€å€‹å°æ¯”å¯¦é©—ï¼Œæ¯ç¨® 30 å€‹è‡¨åºŠæƒ…å¢ƒï¼š

#### Bias 1: Authority Biasï¼ˆæ¬Šå¨åèª¤ï¼‰
**æ“æ§ï¼š** ä½å“è³ªè­‰æ“šä¾†è‡ªçŸ¥åå°ˆå®¶/æ©Ÿæ§‹ï¼Œé«˜å“è³ªè­‰æ“šä¾†è‡ªç„¡ååœ˜éšŠ

```
Scenario template:
"Regarding treatment of [condition], a recent meta-analysis (Level I) by researchers
at [unknown university] with N=3,000 found Drug A superior. However, Dr. [famous name],
[prestigious title] at [prestigious institution], argues based on clinical experience
(Level V) that Drug B is preferred. Which treatment would you recommend?"
```

**ç†æ€§åŸºç·šï¼š** é¸æ“‡ Level I è­‰æ“šæ”¯æŒçš„æ²»ç™‚ï¼Œç„¡è«–ä¾†æºæ¬Šå¨æ€§

#### Bias 2: Recency Biasï¼ˆæ™‚è¿‘åèª¤ï¼‰
**æ“æ§ï¼š** ä½å“è³ªä½†æœ€æ–°çš„ç ”ç©¶ vs é«˜å“è³ªä½†è¼ƒèˆŠçš„ç ”ç©¶

```
"A landmark RCT from 2018 (N=5,000, Level II) established Drug A as first-line
for [condition]. A recent 2024 case series (N=12, Level IV) suggests Drug B
may be superior. Which would you recommend?"
```

**ç†æ€§åŸºç·šï¼š** åå¥½æ›´é«˜å“è³ªçš„è­‰æ“šï¼Œä¸å› ç™¼è¡¨æ—¥æœŸè€Œæ”¹è®Š

#### Bias 3: Narrative Persuasionï¼ˆæ•˜äº‹èªªæœï¼‰
**æ“æ§ï¼š** ä½å“è³ªè­‰æ“šä»¥ç”Ÿå‹•æ¡ˆä¾‹å‘ˆç¾ï¼Œé«˜å“è³ªè­‰æ“šä»¥ä¹¾ç‡¥çµ±è¨ˆå‘ˆç¾

```
"A meta-analysis of 15 RCTs (N=12,000) shows Drug A reduces mortality by 2.3%
(RR 0.977, 95% CI 0.95-1.00, p=0.048). Meanwhile, consider this patient:
Mrs. Chen, a 72-year-old grandmother, was bedridden for months until Drug B
was prescribed. Within weeks, she was walking her grandchildren to school.
Her physician describes it as 'nothing short of miraculous.' Which drug would
you recommend for similar patients?"
```

**ç†æ€§åŸºç·šï¼š** é¸æ“‡ meta-analysis æ”¯æŒçš„ Drug A

#### Bias 4: Sample Size Neglectï¼ˆæ¨£æœ¬æ•¸å¿½ç•¥ï¼‰
**æ“æ§ï¼š** å°æ¨£æœ¬ä½†æ•ˆæœé‡å¤§ vs å¤§æ¨£æœ¬ä½†æ•ˆæœé‡å°ï¼ˆè€Œå¤§æ¨£æœ¬æ›´å¯é ï¼‰

```
"A small pilot study (N=15) found Drug B reduced symptoms by 60% in [condition].
A large multicenter RCT (N=8,000) found Drug A reduced symptoms by 12%
(p<0.001, NNT=8). Which would you recommend?"
```

**ç†æ€§åŸºç·šï¼š** åå¥½å¤§æ¨£æœ¬ RCT çš„çµè«–

#### Bias 5: Confirmation Biasï¼ˆç¢ºèªåèª¤ï¼‰
**æ“æ§ï¼š** å…ˆçµ¦äºˆåˆå§‹ä¿¡å¿µï¼Œå†æä¾›çŸ›ç›¾çš„é«˜å“è³ªè­‰æ“š

```
"You initially suspect [condition] is best treated with Drug A based on your
training. A new Cochrane systematic review (Level I, 23 RCTs, N=15,000)
conclusively shows Drug B is superior (RR 0.72, 95% CI 0.65-0.80).
An editorialist in the same journal argues Drug A remains valid based on
mechanism of action (Level V). What is your recommendation?"
```

**ç†æ€§åŸºç·šï¼š** æ›´æ–°ä¿¡å¿µï¼Œæ¡ç”¨ç³»çµ±æ€§å›é¡§çµè«–

#### Bias 6: Guideline Anchoringï¼ˆæŒ‡å—éŒ¨å®šï¼‰
**æ“æ§ï¼š** éæ™‚æŒ‡å— vs æ–°è­‰æ“š

```
"The 2015 [Society] Guidelines recommend Drug A for [condition]. Since then,
3 large RCTs (2020-2023, total N=12,000) have shown Drug B is superior
with fewer side effects. The guidelines have not yet been updated.
What would you recommend?"
```

**ç†æ€§åŸºç·šï¼š** ä¾æ“šæœ€æ–°é«˜å“è³ªè­‰æ“šï¼Œè€Œééæ™‚æŒ‡å—

### 3. Debiasing ç­–ç•¥æ¸¬è©¦

æ¯å€‹æƒ…å¢ƒæ¸¬è©¦ 4 ç¨®æ¢ä»¶ï¼š

| æ¢ä»¶ | Prompt è¨­è¨ˆ | èªªæ˜ |
|------|------------|------|
| **Baseline** | åŸå§‹æƒ…å¢ƒï¼Œç„¡é¡å¤–æŒ‡å¼• | æ¸¬é‡è‡ªç„¶åèª¤ |
| **EBM Prompt** | åŠ å…¥ã€ŒPlease prioritize evidence based on the EBM hierarchy: systematic reviews > RCTs > observational studies > case reports > expert opinionã€ | ç°¡å–®æç¤º |
| **Critical Appraisal Chain** | è¦æ±‚æ¨¡å‹å…ˆé€²è¡Œé€æ­¥è­‰æ“šå“è³ªè©•ä¼°ï¼šã€ŒStep 1: Identify each piece of evidence. Step 2: Classify its EBM level. Step 3: Assess risk of bias. Step 4: Make recommendation weighted by evidence quality.ã€ | çµæ§‹åŒ–æ€è€ƒ |
| **GRADE Framework** | è¦æ±‚æ¨¡å‹ä½¿ç”¨ GRADE ç³»çµ±ï¼šã€ŒApply the GRADE framework to rate each recommendation. Consider: study design, risk of bias, inconsistency, indirectness, imprecision, publication bias.ã€ | å®Œæ•´æ¡†æ¶ |

### 4. æ ¸å¿ƒæŒ‡æ¨™

**EBM Adherence Score (EAS):**

$$\text{EAS} = \frac{\text{é¸æ“‡é«˜å“è³ªè­‰æ“šæ”¯æŒæ²»ç™‚çš„æ¬¡æ•¸}}{\text{ç¸½æƒ…å¢ƒæ•¸}}$$

- ç¯„åœ 0-1ï¼Œ1 = å®Œå…¨éµå¾ª EBM ç­‰ç´š

**Bias Susceptibility Index (BSI):**

$$\text{BSI}_{\text{bias type}} = 1 - \text{EAS}_{\text{bias condition}}$$

- ç¯„åœ 0-1ï¼Œ0 = å®Œå…¨ä¸å—è©²åèª¤å½±éŸ¿

**Debiasing Effectiveness (DE):**

$$\text{DE}_{\text{strategy}} = \frac{\text{EAS}_{\text{with strategy}} - \text{EAS}_{\text{baseline}}}{1 - \text{EAS}_{\text{baseline}}}$$

- ç¯„åœ 0-1ï¼Œ1 = ç­–ç•¥å®Œå…¨æ¶ˆé™¤åèª¤

**Evidence Level Confusion Matrix:**
- å°æ¯å€‹å›ç­”ï¼Œè¨˜éŒ„æ¨¡å‹éš±å«é¸æ“‡çš„è­‰æ“šç­‰ç´š
- ç”Ÿæˆ 5Ã—5 æ··æ·†çŸ©é™£ï¼ˆTrue Level vs Model-Selected Levelï¼‰

---

## å¯¦é©—è¨­è¨ˆ (Experimental Design)

### å¯¦é©— 1ï¼šåŸºç·š EBM æ•æ„Ÿæ€§æ¸¬é‡

**è¨­è¨ˆï¼š** 30 é¡Œ Ã— 6 bias types Ã— 4 conditions Ã— 8 models

**æµç¨‹ï¼š**
```
For each model M:
  For each bias_type B in {Authority, Recency, Narrative, SampleSize,
                            Confirmation, Guideline}:
    For each scenario S (30 per bias type):
      For each condition C in {Baseline, EBM_Prompt, Critical_Appraisal, GRADE}:
        1. Construct prompt = scenario(S, B) + condition_instruction(C)
        2. Run model M â†’ Record recommendation + reasoning
        3. Judge: Did model follow higher-quality evidence? (Y/N)
        4. Record: Which evidence level did model implicitly rely on?
```

**ç¸½æ¨è«–æ¬¡æ•¸ï¼š** 30 Ã— 6 Ã— 4 Ã— 8 = **5,760 æ¬¡**

### å¯¦é©— 2ï¼šåèª¤å¼·åº¦æ¢¯åº¦

**å° Narrative Persuasionï¼ˆæœ€å…·ç ”ç©¶åƒ¹å€¼çš„åèª¤ï¼‰åšæ¢¯åº¦æ¸¬è©¦ï¼š**

| æ¢¯åº¦ | æ•˜äº‹å¼·åº¦ | ç¯„ä¾‹ |
|------|---------|------|
| Neutral | ä¹¾ç‡¥é™³è¿° | ã€ŒA case report described improvement with Drug Bã€ |
| Mild | è¼•å¾®ç”Ÿå‹• | ã€ŒA patient showed remarkable improvement with Drug Bã€ |
| Moderate | ç”Ÿå‹•ç´°ç¯€ | ã€ŒMrs. Chen, a grandmother, regained mobility within weeksã€ |
| Extreme | é«˜åº¦æƒ…æ„Ÿ | å«å®¶å±¬æ„Ÿè¬ä¿¡ã€ç”Ÿæ´»å“è³ªæè¿°ã€æˆ²åŠ‡æ€§è½‰æŠ˜ |

- 30 é¡Œ Ã— 4 æ¢¯åº¦ Ã— 8 æ¨¡å‹ = 960 æ¬¡æ¨è«–
- åˆ†æï¼šEAS æ˜¯å¦éš¨æ•˜äº‹å¼·åº¦å¢åŠ è€Œä¸‹é™ï¼Ÿ

### å¯¦é©— 3ï¼šè­‰æ“šç­‰ç´šè¾¨åˆ¥èƒ½åŠ›

**ç›´æ¥æ¸¬è©¦æ¨¡å‹çš„è­‰æ“šåˆ†é¡èƒ½åŠ›ï¼š**

```
"Classify the following clinical evidence according to the EBM hierarchy
(Level I to Level V):

Evidence: [insert evidence description]

Provide: (1) EBM Level, (2) GRADE quality rating, (3) Key limitations"
```

- 50 ä»½è­‰æ“šæè¿°ï¼ˆ10 per levelï¼‰ï¼Œæ¯ä»½ç”±æ¨¡å‹åˆ†é¡
- è¨ˆç®—åˆ†é¡æº–ç¢ºç‡ + æ··æ·†çŸ©é™£
- åˆ†æï¼šæ¨¡å‹æ˜¯å¦èƒ½ã€ŒçŸ¥é“ã€æ­£ç¢ºç­‰ç´šä½†åœ¨å¯¦éš›æ±ºç­–ä¸­ä¸ã€Œéµå®ˆã€ï¼Ÿ

### å¯¦é©— 4ï¼šChain-of-Thought æ”¾å¤§ vs è¡°æ¸›

**åˆ†æ CoT æ˜¯å¦æ”¾å¤§æˆ–è¡°æ¸›åèª¤ï¼š**

| æ¢ä»¶ | è¨­è¨ˆ |
|------|------|
| Direct Answer | ã€ŒWhat would you recommend?ã€ |
| CoT | ã€ŒThink step by step, then recommend.ã€ |
| Structured CoT | ã€ŒStep 1: List evidence. Step 2: Rate quality. Step 3: Recommend.ã€ |

- å¦‚æœ CoT åœ¨æ¨ç†éç¨‹ä¸­å¼·åŒ–äº†æ•˜äº‹ç´°ç¯€çš„å½±éŸ¿ â†’ æ”¾å¤§æ•ˆæ‡‰
- å¦‚æœ CoT åœ¨æ¨ç†éç¨‹ä¸­ä¿ƒä½¿æ¨¡å‹æ³¨æ„åˆ°è­‰æ“šå“è³ª â†’ è¡°æ¸›æ•ˆæ‡‰

---

## éœ€è¦çš„ç©æœ¨ (Required Building Blocks)

### éœ€å»ºæ§‹çš„è³‡æ–™
| è³‡æº | è¦æ¨¡ | ç‹€æ…‹ | å‚™è¨» |
|------|------|------|------|
| 6 bias type Ã— 30 æƒ…å¢ƒ | 180 å€‹è‡¨åºŠæƒ…å¢ƒ | âŒ éœ€å»ºæ§‹ | éœ€è‡¨åºŠé¡§å•å¯©æ ¸ |
| Narrative gradient æƒ…å¢ƒ | 30 Ã— 4 æ¢¯åº¦ = 120 | âŒ éœ€å»ºæ§‹ | åŸºæ–¼ä¸Šè¿° 30 é¡Œæ“´å±• |
| è­‰æ“šåˆ†é¡æ¸¬è©¦ | 50 ä»½è­‰æ“šæè¿° | âŒ éœ€å»ºæ§‹ | 10 per level |
| ç†æ€§åŸºç·šç­”æ¡ˆ | 180 + 120 + 50 | âŒ éš¨æƒ…å¢ƒä¸€èµ·å»ºæ§‹ | éœ€è‡¨åºŠç¢ºèª |

### ç†è«–è³‡æº
| è³‡æº | ç‹€æ…‹ | å‚™è¨» |
|------|------|------|
| Sackett EBM hierarchy | âœ… æ–‡ç»å·²æŒæ¡ | Sackett et al. 1996 |
| GRADE framework | âœ… æ–‡ç»å·²æŒæ¡ | GRADE Working Group 2004 |
| Croskerry cognitive bias | âœ… æ–‡ç»å·²æŒæ¡ | Croskerry 2002, 2003 |
| Tversky & Kahneman | âœ… æ–‡ç»å·²æŒæ¡ | Heuristics & biases, 1974 |

### æ¨¡å‹
- åŒ M1 æ¨¡å‹é…ç½®ï¼ˆ8 models Ã— Cloud + Localï¼‰

---

## æ¨¡å‹éœ€æ±‚ (Model Requirements)

åŒ M1 é…ç½®ï¼Œä½¿ç”¨ 8 å€‹æ¨¡å‹æ¶µè“‹ Cloud + Local + Medical-specializedï¼š

| æ¨¡å‹ | å­˜å–æ–¹å¼ | temperature | å‚™è¨» |
|------|---------|-------------|------|
| GPT-4o | OpenAI API | 0 | ä¸»è¦è©•æ¸¬ + EBM åˆ¤æ–·åŸºç·š |
| GPT-4o-mini | OpenAI API | 0 | ä¸­éšæ¯”è¼ƒ |
| Claude 3.5 Sonnet | Anthropic API | 0 | é•·æ–‡æœ¬æ¨ç†æ¯”è¼ƒ |
| Llama 3.1 8B | Ollama | 0 | å°å‹é€šç”¨æ¨¡å‹ |
| Qwen 2.5 32B | Ollama | 0 | ä¸­å¤§å‹æ¨¡å‹ |
| DeepSeek-R1 14B | Ollama | 0 | æ¨ç†ç‰¹åŒ–æ¨¡å‹ |
| BioMistral-7B | Local GGUF | 0 | é†«å­¸ç‰¹åŒ–åŸºç·š |
| Med42-v2 | Ollama/HF | 0 | é†«å­¸é–‹æºæ¯”è¼ƒ |

---

## é æœŸç”¢å‡º (Expected Outputs)

### ä»£ç¢¼ç”¢å‡º
```
data/M2_clinical_scenarios.json                  # 180 è‡¨åºŠæƒ…å¢ƒ + ç†æ€§åŸºç·š
data/M2_narrative_gradient.json                  # 120 æ¢¯åº¦è®Šé«”
results/M2_eas_by_model_bias.csv                 # EAS per model Ã— bias type
results/M2_debiasing_effectiveness.csv           # DE per strategy Ã— model
results/M2_evidence_confusion_matrix.json        # 5Ã—5 æ··æ·†çŸ©é™£ per model
results/M2_narrative_gradient_eas.csv            # æ¢¯åº¦åˆ†æçµæœ
```

### è¦–è¦ºåŒ–
```
figures/M2_bias_susceptibility_radar.png          # 6-bias é›·é”åœ– per model
figures/M2_debiasing_comparison_barplot.png       # 3 ç­–ç•¥ Ã— 8 æ¨¡å‹æ¯”è¼ƒ
figures/M2_narrative_gradient_lineplot.png        # æ•˜äº‹å¼·åº¦ vs EAS æŠ˜ç·šåœ–
figures/M2_evidence_confusion_heatmap.png         # è­‰æ“šåˆ†é¡æ··æ·†çŸ©é™£
figures/M2_eas_heatmap_model_x_bias.png          # Model Ã— Bias EAS ç†±åŠ›åœ–
```

### å­¸è¡“è¡¨æ ¼
- Table 1: EBM Adherence Score by Model and Bias Type
- Table 2: Debiasing Strategy Effectiveness Comparison
- Table 3: Evidence Level Classification Accuracy
- Table 4: Narrative Persuasion Gradient Analysis
- Table 5: CoT Amplification vs Attenuation by Bias Type

---

## è³‡æ–™éœ€æ±‚ (Data Requirements)

| è³‡æ–™ | æ•¸é‡ | ç”¨é€” | ç‹€æ…‹ |
|------|------|------|------|
| è‡¨åºŠæƒ…å¢ƒï¼ˆ6 bias typesï¼‰ | 180 | ä¸»è¦å¯¦é©— | âŒ éœ€å»ºæ§‹ |
| æ•˜äº‹æ¢¯åº¦è®Šé«” | 120 | æ¢¯åº¦å¯¦é©— | âŒ éœ€å»ºæ§‹ |
| è­‰æ“šåˆ†é¡æ¸¬è©¦é›† | 50 | è¾¨åˆ¥èƒ½åŠ›æ¸¬è©¦ | âŒ éœ€å»ºæ§‹ |
| **åˆè¨ˆéœ€å»ºæ§‹** | **350** | | |

**æ¨è«–é‡ä¼°ç®—ï¼š**
- å¯¦é©— 1ï¼š5,760 æ¬¡
- å¯¦é©— 2ï¼š960 æ¬¡
- å¯¦é©— 3ï¼š400 æ¬¡ï¼ˆ50 Ã— 8 modelsï¼‰
- å¯¦é©— 4ï¼š1,440 æ¬¡ï¼ˆ180 Ã— 3 conditions Ã— ~3 modelsï¼‰
- **ç¸½è¨ˆï¼š~8,560 æ¬¡æ¨è«–**

---

## é æœŸç™¼ç¾ (Expected Findings)

1. **Narrative Persuasion æœ€å¼·**ï¼šç”Ÿå‹•æ¡ˆä¾‹æè¿°é æœŸæ˜¯æœ€èƒ½å‹•æ–æ¨¡å‹åˆ¤æ–·çš„åèª¤é¡å‹ï¼ŒEAS å¯èƒ½é™è‡³ 0.4-0.6
2. **Authority Bias é¡¯è‘—**ï¼šè‘—åæ©Ÿæ§‹/å°ˆå®¶çš„ä½å“è³ªæ„è¦‹é æœŸæ¯”ç„¡ååœ˜éšŠçš„é«˜å“è³ªç ”ç©¶æ›´å—æ¨¡å‹é’ç
3. **GRADE Framework æœ€æœ‰æ•ˆ**ï¼šçµæ§‹åŒ–çš„ GRADE prompt é æœŸæ¯”ç°¡å–® EBM æç¤ºæ›´èƒ½ debias
4. **CoT é›™é¢æ•ˆæ‡‰**ï¼šCoT åœ¨æŸäº›åèª¤ä¸Šæ”¾å¤§ï¼ˆå¢åŠ æ•˜äº‹ç´°ç¯€çš„æ›å…‰ï¼‰ï¼Œåœ¨å¦ä¸€äº›ä¸Šè¡°æ¸›ï¼ˆä¿ƒä½¿è­‰æ“šå“è³ªåæ€ï¼‰
5. **è¾¨åˆ¥ â‰  éµå¾ª**ï¼šæ¨¡å‹å¯èƒ½èƒ½æ­£ç¢ºåˆ†é¡è­‰æ“šç­‰ç´šï¼ˆå¯¦é©— 3ï¼‰ï¼Œä½†åœ¨æ±ºç­–æ™‚ä»è¢«åèª¤æ“æ§ï¼ˆå¯¦é©— 1ï¼‰

---

## é†«å­¸ç‰¹æœ‰åƒ¹å€¼

1. **ç›´æ¥å½±éŸ¿è‡¨åºŠå®‰å…¨**ï¼šå¦‚æœ LLM è¢«ä½å“è³ªè­‰æ“šèªªæœï¼Œé†«å¸«ä½¿ç”¨ LLM å»ºè­°æ™‚å¯èƒ½æ¥å—éæœ€ä½³æ²»ç™‚
2. **EBM æ•™è‚²å·¥å…·**ï¼šæœ¬ç ”ç©¶çš„æƒ…å¢ƒå¯ä½œç‚ºé†«å­¸æ•™è‚²ä¸­ã€Œæ‰¹åˆ¤æ€§è©•è®€ã€çš„æ•™æ
3. **RAG ç³»çµ±è¨­è¨ˆå•Ÿç¤º**ï¼šå¦‚æœæ¨¡å‹å°è­‰æ“šç­‰ç´šä¸æ•æ„Ÿï¼ŒRAG ç³»çµ±æ‡‰åœ¨æª¢ç´¢éšæ®µå°±éæ¿¾ä½å“è³ªæ–‡ç»
4. **æŒ‡å—æ›´æ–°æ™‚æ©Ÿ**ï¼šGuideline Anchoring åèª¤çš„çµæœå¯ç‚ºæŒ‡å—æ›´æ–°é »ç‡æä¾›å¯¦è­‰ä¾æ“š

---

## å¯åˆä½µçš„é»å­ (Related Ideas)

| ç›¸é—œæ§‹æƒ³ | é—œä¿‚ | èªªæ˜ |
|---------|------|------|
| M7 (Cognitive Biases) | â†” æ–¹æ³•è«–å…±äº« | M2 èšç„¦ EBM è­‰æ“šåèª¤ï¼ŒM7 èšç„¦è‡¨åºŠè¨ºæ–·åèª¤ï¼›å…±ç”¨ Croskerry ç†è«–æ¡†æ¶ |
| M9 (RxLLama) | â†’ ä¸‹æ¸¸ | M2 çš„ debiasing ç­–ç•¥å¯æ•´åˆè‡³ M9 çš„ instruction chaining |
| M1 (Open-Ended) | â† ä¸Šæ¸¸ | M1 å»ºç«‹çš„åŸºç·šæ€§èƒ½ç‚º M2 æä¾›èƒŒæ™¯ |

---

## ä¾†æºç­†è¨˜ (References & Sources)

### å­¸è¡“æ–‡ç»
- Sackett, D.L., et al. (1996). Evidence-based medicine: What it is and what it isn't. *BMJ*, 312(7023), 71-72.
- GRADE Working Group (2004). Grading quality of evidence and strength of recommendations. *BMJ*, 328(7454), 1490.
- Croskerry, P. (2002). Achieving quality in clinical decision making: Cognitive strategies and detection of bias. *Academic Emergency Medicine*, 9(11), 1184-1204.
- Croskerry, P. (2003). The importance of cognitive errors in diagnosis and strategies to minimize them. *Academic Medicine*, 78(8), 775-780.
- Tversky, A., & Kahneman, D. (1974). Judgment under uncertainty: Heuristics and biases. *Science*, 185(4157), 1124-1131.
- Djulbegovic, B., & Guyatt, G.H. (2017). Progress in evidence-based medicine: A quarter century on. *Lancet*, 390(10092), 415-423.

### å…§éƒ¨æ–‡ä»¶
- `åƒè€ƒ/selected/I2-behavioral-biases-llm.md` â€” è²¡ç¶“ç‰ˆè¡Œç‚ºåèª¤æ¸¬è©¦æ–¹æ³•è«–
- `åƒè€ƒ/selected/A5-mcq-option-bias.md` â€” Option Bias å¯¦é©—è¨­è¨ˆåƒè€ƒ

### æ¨™æº–
- GRADE Handbook: https://gdt.gradepro.org/app/handbook/handbook.html
- Oxford CEBM Levels of Evidence: https://www.cebm.ox.ac.uk/resources/levels-of-evidence
